Wednesday, February 13, 2013

MDCO, Bristol-Myers Squibb begin global alliance for Recothrom

The global license and two-year collaboration signed between the Medicines Company (MDCO) and Bristol-Myers Squibb (BMS) for Recothrom, a recombinant thrombin approved by the US Food and Drug Administration (FDA) for use as a topical hemostat to control non-arterial bleeding during surgical procedures has become effective.

The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Glenn Sblendorio, president and chief financial officer of The Medicines Company, said, "We look forward to the start of our global license and collaboration for Recothrom. We believe that completing this deal is another step to establish The Medicines Company as a leader in acute and intensive care medicine globally."

Recothrom is a surgical hemostat that is applied topically to stop bleeding during surgery. Its active ingredient is recombinant human thrombin (rThrombin) and the product is indicated as an aid to hemostasis whenever control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical. Recothrom is part of a class of surgical hemostats commonly referred to as "active" hemostats. Other classes of surgical hemostats include mechanical hemostats, flowable hemostats and fibrin sealants. Recothrom was approved in the United States in January 2008 and in Canada in December 2010.

The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide.

1 comment:

Anonymous said...

Technically, thrombins are classified as passive hemostats, because they require the patient's body to provide one or more essential components (other than water)for hemostasis.

In this case, fibrinogen & Factor XIII are all required for correct product function. Therefore it may fail to function properly in some Patients in which there is a deficiency of one or more of these coagulation components. Thi sis an important clinical distinction between passive hemostats and active hemostats that provide all that is necessary for coagulation to occur, regardless of the condition of the Patient.